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Abstract
Background: A novel non-invasive asthma prediction tool from the Leicester
Cohort, UK, forecasts asthma at age 8 years based on 10 predictors assessed in
early childhood, including current respiratory symptoms, eczema, and parental
history of asthma.
Objective:We aimed to externally validate the proposed asthma prediction method
in a German birth cohort.
Methods: The MAS-90 study (Multicentre Allergy Study) recorded details on
allergic diseases prospectively in about yearly follow-up assessments up to age 20
years in a cohort of 1,314 children born 1990. We replicated the scoring method
from the Leicester cohort and assessed prediction, performance and discrimination.
The primary outcome was defined as the combination of parent-reported wheeze
and asthma drugs (both in last 12 months) at age 8. Sensitivity analyses assessed
model performance for outcomes related to asthma up to age 20 years.
Results: For 140 children parents reported current wheeze or cough at age 3
years. Score distribution and frequencies of later asthma resembled the Leicester
cohort: 9% vs. 16% (MAS-90 vs. Leicester) of children at low risk at 3 years had
asthma at 8 years, at medium risk 45% vs. 48%. Performance of the asthma
prediction tool in the MAS-90 cohort was similar (Brier score 0.22 vs. 0.23) and
discrimination slightly better than in the original cohort (area under the curve, AUC
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0.83 vs. 0.78). Prediction and discrimination were robust against changes of
inclusion criteria, scoring and outcome definitions. The secondary outcome
‘physicians’ diagnosed asthma at 20 years’ showed the highest discrimination
(AUC 0.89).
Conclusion: The novel asthma prediction tool from the Leicester cohort, UK,
performed well in another population, a German birth cohort, supporting its use and
further development as a simple aid to predict asthma risk in clinical settings.
Introduction
Our understanding of modifiable and non-modifiable determinants influencing
the onset and development of asthma in adolescence advanced in recent years, but
it has not lead to improved prevention strategies [1–6].
While primary prevention is lacking, the knowledge about essential parameters
gathered in research can at least be used to predict future asthma in the clinical
setting. Screening children in preschool age to identify those with a high
probability of later asthma opens the opportunity for interventions aiming to slow
or stop progression or modify disease severity at pre-clinical stages. Prediction or
early diagnosis allows for learning about the immunologic processes at work
before obvious symptoms occur.
For example, crude definitions of suggestive symptoms and aspects of patient’s
history are already used in current guidelines to evaluate risk and to target trial
treatment (eg, inhaled corticosteroids, [7, 8]). Several formalized prediction
algorithms have been proposed to quantify the information content of symptoms,
behavioural patterns and heredity for estimating probabilities of later asthma [9–
12].
In a recent issue of the Journal of Allergy and Clinical Immunology, Pescatore et
al. [13] introduced a new 10-item asthma prediction tool, based mainly on
indicative symptoms, and accounting for age, sex, comorbid eczema and parents’
history of asthma/bronchitis. Unlike prior studies, final selection of variables/
predictors was run by a LASSO-penalized regression model, homing on fewer
factors and higher external validity (Least Absolute Shrinkage and Selection
Operator).
None of these scoring systems is widely used in primary care [14]. This is
mainly due to the lack of external validation and impact studies, requisites for a
general recommendation of such tools [15]. The predictive performance outside
the population from which the tool was developed is usually lower than estimated
from internal validation, both in retrospective as well as prospective external
validation studies [16–19]. Pescatore et al. validated the new asthma prediction
tool in the cohort used for development itself [13, 20], which now requires
replication in other populations [21] as the most rigorous assessment of a model’s
validity [22].
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Our aim was therefore to externally validate Pescatore’s asthma prediction tool
by estimating measures of discrimination, calibration and performance in the
MAS-90 birth cohort [23, 24], supported by sensitivity analyses considering
different inclusion criteria for validation sample, scoring items, and outcome
definitions, and assessing asthma phenotypes up to 20 years.
Methods
For external validation of the novel asthma prediction tool we retrospectively
applied the suggested scoring to a subsample of the MAS-90 birth cohort.
Exploring the robustness of the primary model and accounting for differences in
data collection, we reiterated analyses with various definitions of inclusion,
scoring and outcome criteria as described below.
Setting
From all 7,609 children born during 1990 in 6 participating hospitals across
Germany, a population-based birth cohort was recruited (n51,314, The German
Multicentre Allergy Study, MAS-90). Newborns to allergic parents, based on
history or positive Immunoglobulin E screening were partly oversampled (19% in
all children vs. 38% in the recruited cohort, details in [23, 25, 26]). Development
of allergic diseases including asthma as well as information on living environment
and lifestyle were traced at nineteen time points up to age 20 years through
interviews, questionnaires, clinical investigations including blood sampling and
assessment of lung function, achieving a long-term response of 72% at 20 years.
The project was approved by local institutional review boards (ethics committees
Charite´ – Universita¨tsmedizin Berlin; Technical University Munich, Faculty of
Medicine; Landesa¨rztekammer Rheinland-Pfalz; University Medical Hospital
Freiburg). All parents and later all adult participants provided written informed
consent for data collection and analysis.
Population and inclusion criteria
The sample used for external validation was limited to children who participated
in assessments at 3 and 8 years (7th and 12th follow-up). Resembling the
development cohort [13], our primary inclusion criteria were further restricted to
participants reporting wheeze (‘Has your child had wheezing or whistling in the
chest in the last 12 months?’) or cough (‘In the last 12 months, has your child had
a dry cough at night, apart from a cough associated with a cold or a chest
infection?’) in 3 years’ interview. For sensitivity analyses, secondary sample
inclusion criteria comprise the whole initial sample irrespective of symptoms at 3
years, and those reporting either wheeze or cough only.
External Validation of Asthma Prediction Tool
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Scoring variables
Six of the 10 items of the original asthma prediction tool refer to parent-reported
symptoms (questions 3–8). For the (primary) scoring definition we manually
identified corresponding items from the interview at 3 years in the MAS-90
cohort. Child’s sex was documented at recruitment (baseline assessment), age was
calculated from date of birth and interview (questions 1, 2). Information on
comorbid eczema and parents’ allergies were derived from the interview at 3 years
(questions 9, 10). Several secondary scoring approaches were assessed. Questions
on eczema and parents’ allergies asked at 3 years of age covered only the previous
12 months, and were thus complemented with data from earlier follow-ups and
baseline. Secondly, all missing information (answer ‘Always’ in question 6,
question 8 entirely) was imputed at random. Finally, actual scores were shuffled at
random between study participants, giving reference measures of discrimination
and performance.
Outcomes
As used for model development, parent-reported current wheeze (‘Has your child
had wheezing or whistling in the chest in the last 12 months?’) in combination
with use of asthma drugs (‘Did your child take any drugs against asthma during
the last 12 months?’) both at age 8 years was defined as the primary outcome.
As secondary outcomes, wheeze or asthma drugs only, and a physician’s
diagnosis of asthma were used as reported at the eight-year-follow-up. Another set
of secondary outcome definitions used information collected in the MAS-90
cohort in later assessments up to age 20 years. For these outcome definitions
asthma was defined as satisfying 2 of the following 3 criteria at any follow-up from
age three years and above: physician’s diagnosis of asthma ever; asthma drugs in
last 12 months; any indicative symptom in last 12 months (wheezing, shortness of
breath, dry cough at night). Allergic asthma further included a positive serum
specific immunoglobulin E$0.35 kU/l (kilo Units per litre) to at least one
regularly assessed aero-allergen (dust mite, dog, cat, birch, timothy), determined
at nine time points (ImmunoCAP – Phadia GmbH, Freiburg, Germany). Lung
function at 20 years was assessed through escalating-dose Methacholine challenge,
a$20% drop of FEV1 (Forced Expiratory Volume in 1 second) from baseline was
considered as increased airway responsiveness.
Statistical methods
Data management, data cleaning and statistical evaluation was carried out using
the SAS system (version 9.3, SAS Institute Inc., Cary NC, USA). Children with
missing information on one of the two items used for inclusion or one of the two
used for the primary outcome definition were excluded from this analysis. Missing
questionnaire items used for scoring were set to the baseline value of zero (items 3
to 10) for the primary approach. Random imputation of missing questions/
answer categories (eg question 6, 8) in the validation cohort used frequency
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estimates from the development dataset. For random imputation of the total score
we reshuffled the validation cohort’s actual scores between individuals. Both
imputations were run 100 times, measures of performance averaged, and in-
between imputation variation accounted for the calculation of confidence
intervals. These approaches will not add further insight to the performance of the
score, but allows assessment of robustness. Reshuffling the scores randomly gives
non-informative point and precision estimates, facilitating interpretation of real
performance measures. The actual score distribution in the development cohort
was inferred from tabulated sensitivity and specificity, as it was not published in
the original article.
A univariate logistic model was used to derive measures of test performance
(sensitivity, specificity, predictive values, likelihood ratios) and disease probability
for each score, resembling what was reported originally. Odds ratio for developing
asthma per 1-point increase of the score at 3 years as well as Nagelkerke’s R2
(maximum rescaled R2, coefficient of determination standardized to its
maximum) and maximum rescaled Brier score were calculated as overall
performance measures [24]. The Brier score is a measure of how well the
predicted and the actual outcomes overlap: with a value of 0 the model adds no
information to the a-priori prevalence, and a value of 1 indicates best-possible
prediction. Discrimination was reported using the c statistic (AUC, area under
curve), calibration/agreement was assessed graphically plotting predicted disease
frequency in eight groups against observed disease frequency.
Results
Study population
Our sample from the MAS-90 cohort is similar to the cohort population the score
was developed in, with respect to prospective regular assessments. Unlike in the
original cohort from Leicester, UK, where children were enrolled aged 1 to 3, the
German MAS-90 participants were all recruited at birth and allergic parents were
slightly oversampled (table 1).
841 of 1,314 (64%) study participants completed follow-up assessments at 3
and 8 years, of which 140 (17%) met the primary inclusion criteria: wheeze or
cough in the previous 12 months at age 3 years. This primary study sample was
similar to all followed, in terms of parental education and overweight, family’s
smoking habits, and atopic heredity (parents’ self-reported allergies and cord
blood Immunoglobulin E, table 2). 121 children from the primary sample (86%)
were successfully traced up to the age of 20 years, out of which 93 (77%)
underwent lung function testing.
Scoring
We identified corresponding items in the 3-year-questionnaire for 9 of 10 original
scoring questions, 5 with perfect/very good and 1 with good comparability. One
External Validation of Asthma Prediction Tool
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question (item 5, wheeze interfering with daily activities) was not asked in the
validation cohort, but could be substituted by a proxy question on sleep
disturbance by wheeze. One question (item 8, cause of wheeze/cough) could not
be replaced by a meaningful alternative, which was assessed in sensitivity analyses
as described later (table 3).
Frequency of answers was similar in the validation cohort compared to the
original population for most items, except for shortness of breath at 16% vs. 35%
in development cohort and wheezing caused by ‘physical stress’ at 19% vs. 39% in
development cohort, which asked for wheezing caused by ‘exercise, laughing,
Table 1. Comparison of study characteristics.
Development cohort External validation cohort
Location Leicester (United Kingdom) Berlin, Du¨sseldorf, Freiburg, Mainz, Munich (Germany)
Climate humid temperate maritime humid temperate maritime/continental
Year of birth 1995–97 1990
Male sex 52% 52%
Study design prospective cohort (birth and later) prospective birth cohort
Recruitment general population random sample population-based (partly risk-enriched regarding parental allergy)
Ethnicity (mother) 81% Caucasian 19% south Asian ethnicity unknown, predominantly Caucasian
Age at scoring (median) 2 years 3 years
doi:10.1371/journal.pone.0115852.t001
Table 2. Characteristics of families in sample used for external validation, by follow-up status.
assessed at 3 and 8y loss to follow-up
met primary inclusion
criteria
n % [95%-CI] n % [95%-CI] n % [95%-CI]
All 841 100 473 100 140 100
Parental educational level
low (ISCED 1/2) 143 18 [16;20] 122 28 [24;32] 26 20 [12;28]
medium (ISCED 3/4) 337 43 [39;46] 187 43 [39;47] 52 40 [32;49]
high (ISCED 5/6) 312 39 [36;43] 128 29 [25;32] 51 40 [33;48]
Overweight (BMI $25 kg/m2)
mother 122 18 [15;21] 35 25 [17;31] 15 14 [7;19]
father 280 44 [40;49] 58 48 [38;58] 38 40 [33;48]
Smoking
at home 439 56 [53;60] 289 82 [78;86] 73 55 [48;61]
during pregnancy 89 11 [10;14] 82 19 [15;23] 18 13 [9;18]
Asthma, allergic rhinitis or eczema
parents not allergic 412 50 [45;54] 252 55 [51;59] 55 40 [32;47]
mother or father 324 39 [36;44] 154 34 [30;38] 61 45 [38;52]
both parents 87 11 [8;13] 52 11 [7;13] 21 15 [9;22]
Cord blood IgE $0.35 kU/l 288 36 [32;39] 163 36 [31;39] 56 43 [36;50]
ISCED, International Standard classification of Education; BMI, Body mass index; IgE, Immunoglobulin E; 95%-CI, bootstrapped 95% confidence intervals;
kU/l, kilo Units per litre.
doi:10.1371/journal.pone.0115852.t002
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Table 3. Questionnaire items used for scoring.
Question in asthma prediction score [13] (%)
Questionnaire
item in MAS-90
(3y-follow-up) (%) Comparability
1. What is the child’s sex? Female 50 (45) [assessed at
baseline]
Female 50 (46) perfect
Male 51 (55) Male 51 (54)
2. How old is the child? (in years) 150 (28) [calculated
from date of
birth and date
at 3y-follow-up]
- - Perfect (limited to
3y)
251 (57) - -
351 (15) 351 (100)
3. In the last 12 months, has the child had
wheezing or whistling in the chest even
without having a cold or flu?
No 50 (82) Did this wheez-
ing or whistling
go along with a
cold or flu?
Always/Don’t
know 50
(83) very good (nega-
tion of question)
Yes 51 (18) No/Sometimes 51 (17)
4. How many attacks of wheeze has the
child had during the last 12 months?
0-350 (45) How many
attacks of
wheezing or
asthma has
your child had
during the last
12 months?
0-350 (47) very good (asthma
included)
.352 (55) .3 (3 cat.) 52 (53)
5. In the last 12 months, how much did
wheezing interfere with your child’s daily
activities?
Never 50 (64) In the last 12
months, how
often, on aver-
age, has your
child’s sleep
been disturbed
due to wheezing
or asthma?
Never 50 (67) Moderate (proxy
measure of sever-
ity)
A little 51 (26) Only at attacks 51 (26)
A lot 52 (10) Regularly (3 cat.)
52
(7)
6. Do these wheezing attacks cause
him/her to be short of breath?
Never 50 (65) In the last 12
months, was an
attack of wheez-
ing or asthma
severe enough
that your child
had to take a
breath after one
or two words?
No 50 (84) Moderate (answer
category miss-
ing)
Sometimes
52
(29) Yes 52 (16)
Always 53 (6) - -
7. In the last 12 months, did exercise
(playing, running) or laughing, crying
or excitement cause wheezing or
coughing in the child?
No 50 (61) In the last 12
months, did
physical stress
cause wheezing
in the child?
No 50 (81) Good (cough not
included, different
answers not
listed)
Yes 51 (39) Yes 51 (19)
External Validation of Asthma Prediction Tool
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crying or excitement’. Furthermore, parents’ respiratory illness was more
common in the Leicester population asking for wheeze, asthma and bronchitis
(mother 22%/father 17%), compared to MAS-90 where the question was limited
to asthma only (8%/6%).
The distribution of actual scores in the validation cohort (mean score 4.2,
median 4) was very similar to what we derived from the report of Pescatore et al.
(mean score 4.5, median 4). Only the high risk group (score $10) was
considerably smaller in our sample with 2% vs. 8% (Fig. 1).
Outcomes
28 of 140 children (20%) who wheezed or coughed at 3 years of age met the
primary outcome definition of asthma at 8 years (wheeze combined and asthma
medication, both parent-reported). Regarding specific symptoms, 33 (26%)
reported wheeze, 33 (26%) recent use of asthma drugs, and 27 (19%) a physician’s
diagnosis of asthma. 51 of 121 children (42%) followed up to 20 years developed
asthma between 3 and 20 years, the majority was sensitized to aero-allergens
(84%). 29 of 93 (31%) participants at age 20 reacted to Methacholine challenge in
lung function testing. In the low risk group (score #5) asthma prevalence at 8
years was 9% (vs. 16% in original cohort), in those at medium risk (score 6–9)
45% (vs. 48%). Items used for inclusion and the primary outcome definition were
comparable between the original and the validation cohort (table 4).
Table 3. Cont.
Question in asthma prediction score [13] (%)
Questionnaire
item in MAS-90
(3y-follow-up) (%) Comparability
8. In the last 12 months, did contact with dust,
grass, pets or other animals cause wheezing
or coughing in the child?
No 50 (93) [no comparable
item available]
-
Yes 51 (7)
9. Has the child ever had eczema? No 50 (56) In the last 12
months, has
your child had
eczema?
No 50 (63/25*) very good (last 12
months vs. ever)
Yes 51 (44) Yes 51 (37/75*)
10. Have the child’s parents ever suffered from
wheezing, asthma or bronchitis?
None 50 (52) In the last 12
months, did the
child’s mother/
father suffer
from asthma?
No 50 (86/48*) Moderate (wheez-
ing/bronchitis not
included, last 12
months vs. ever)
Mother 51 (22) Mother 51 (8/34*)
Father 51 (17) Father 51 (6/29*)
Numbers in brackets (%) are frequencies of parents’ answers, denominator of n51226 in Leicester subsample used for generating the tool, and of n5140 in
MAS-90 subsample. * before/after imputation with values from prior follow-up assessments and baseline.
doi:10.1371/journal.pone.0115852.t003
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Model performance
Performance of the primary model in our sample was similar to the original
cohort with sensitivity of 82% (original cohort 72%) and specificity of 69%
(original cohort 71%) at score 5. Predicted disease probability at score 5 was 20%,
by chance the same as the a priori disease frequency (Fig. 2). Overall performance
of the primary model resembled the original analysis with a max-rescaled Brier
score of 0.22, Nagelkerke’s R2 (max-rescaled) of 0.32 and an odds ratio of 1.7
(95% confidence interval 1.4–2.1). Discrimination between asthma vs. no asthma
at age 8 years was better in our sample with an AUC (area under the curve) of 0.83
(95% confidence interval 0.75–0.91), compared to 0.78 in the Leicester sample.
Replacing the primary case definition with a physician’s diagnosis of asthma led to
an even higher AUC of 0.89 (Fig. 3). Graphical assessment of agreement between
observed and predicted disease frequencies revealed very good calibration of the
original model (Fig. 4).
Sensitivity analyses
We reiterated discrimination and performance assessment for various inclusion,
scoring and outcome criteria. The model performed best using cough as the only
inclusion criterion at 3 years (AUC 0.91, Brier score 0.45) or a physician’s
diagnosis of asthma as outcome definition at 8 years (AUC 0.89, Brier score 0.34).
The model performed poorly in predicting response to the Methacholine
Fig. 1. Score distribution (relative frequency) from model building sample. (n51226, left side, from [13])
and external validation sample (n5140, right side). Primary inclusion, scoring and outcome definitions. * no
child with age 1 year in external validation sample (score 0 not possible).
doi:10.1371/journal.pone.0115852.g001
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challenge at 20 years (AUC 0.64, Brier score 0.05). Randomly reshuffled scores
showed, expectedly, no discrimination and prediction (table 5).
Discussion
Key results
We externally validated the recently developed asthma prediction tool [13]
retrospectively on follow-up data of the German MAS-90 birth cohort study,
which resembles major design aspects of the original cohort from Leicester, UK
[20]. 9 of 10 scoring items were successfully mapped to our questionnaire at 3
years of age, with similar answer frequencies compared to the development
cohort. The final score distribution and asthma frequencies at 8 years within low
(9% reported asthma), middle (45%) and high risk (67%) score groups were close
to the original sample. Measures of performance were similar (max-rescaled Brier
score 0.22, max-rescaled/Nagelkerke’s R2 0.32) and discrimination slightly better
(AUC 0.83) compared to the Leicester sample (AUC 0.78). Sensitivity analyses
revealed robust prediction for various definitions of inclusion, scoring and
Table 4. Questionnaire items used as inclusion criteria and outcome definition, comparing original and validation cohort.
Leicester cohort: Items for inclusion criteria (at age 1-3
years) MAS-90 cohort: Items for inclusion criteria (at age 3 years) Comparability
Has your child had wheezing
or whistling in the chest in the
last 12 months?
yes, no Has your child had wheezing
or whistling in the chest in
the last 12 months?
yes, no perfect
Does your child usually have
a cough apart from colds?
yes, no [no comparable item
available]
- undefined use in [13]
In the last 12 months, has
your child had a dry cough
at night, apart from a cough
associated with a cold or a
chest infection?
yes, no In the last 12 months, has
your child had a dry cough
at night, apart from a cough
associated with a cold or
a chest infection?
yes, no perfect
How often did your child see
a GP for coughing or wheezing
during the last 12 months?
never, once, 2–3 times,
4–6 times, 7 or more
times
[no comparable item
available]
- -
In the last 12 months, has
wheezing or asthma resulted
in your child: [4 categories:
referred/admitted to hospital,
attending/calling ER or GP]
yes, no [no comparable item
available]
- undefined use in [13]
Leicester cohort: Items for
outcome definition (at age
8 years)
MAS-90 cohort: Items
for outcome definition
(at age 8 years)
Has your child had wheezing
or whistling in the chest in
the last 12 months?
yes, no Has your child had wheezing
or whistling in the chest
in the last 12 months?
yes, no perfect
Did your child take any of the
following during the last 12
months? [4 categories: inhalers
by content/type]
yes, no, don’t know Did your child take any
drugs (syrup, tablets
or spray) against breathing
difficulties during the last
12 months?
yes, no Moderate (no details on
drugs taken)
doi:10.1371/journal.pone.0115852.t004
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outcome criteria, with even better discrimination using the stringent outcome
definition of asthma diagnosed by a physician (AUC 0.89).
Strengths and limitations
This retrospective validation analysis was made possible because follow-up
assessments in the MAS-90 cohort included all data necessary to derive inclusion
criteria, information for scoring according to the ten original asthma prediction
tool questions, and outcome definitions. Such rare opportunity is an ideal setting
for external validation: a similar population unrelated in terms of location and
sampling, assessed with the same or similar tools [15].
In the original cohort inclusion was based on the report of wheeze or cough at 3
years, for the assessment at 2 years (median age of original cohort) did not include
these and other information necessary for scoring, and used the exact same
questionnaire wording as we did in our birth cohort. The original sample was
further limited to those having recently seen a physician in response to these
symptoms. Such information was not collected in the MAS-90 cohort and could
not be replaced by proxy data. But model performance and discrimination was
Fig. 2. Predicted probability of developing asthma 5 years later, for a single particular score value. Performance measures by score in table above.
Primary inclusion, scoring, and outcome definitions. Probabilities from original paper (dotted line). * Values not meaningful and/or no accurate estimate
possible. PPV/NPV, positive/negative predictive value; LR+/-, positive/negative likelihood ratio.
doi:10.1371/journal.pone.0115852.g002
External Validation of Asthma Prediction Tool
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similar applying different (secondary) inclusion criteria, with the subsample of
children reporting wheeze giving the poorest discrimination (AUC 0.72) and
those with cough the highest (AUC 0.91). Compared to recommended sample
sizes for validation studies, the validation sample yielded a limited number of
events and non-events [27], with slightly less precise estimates in the validation
cohort.
Only little information necessary to calculate the exact score for each child was
missing in our sample, either because it was missing by item or the according
question was not asked or phrased differently. We approached the latter by
mapping related questionnaire items containing proxy information. The two
secondary definitions used for scoring gave almost identical performance and
discrimination, one complementing data from earlier follow-up assessments, the
other iteratively imputing missing items with random values. The minor
difference in risk distribution with lower numbers for the highest scores in our
sample and the predominantly Caucasian population limit generalizability of this
Fig. 3. Receiver Operating Characteristic (ROC) using external validation sample. Primary inclusion and
scoring definitions. Outcome definitions: Primary (current wheezing and asthma drugs at 8y, solid line) and
secondary (physician’s diagnosed asthma at 8y, dashed line). Numbers indicate asthma prediction score
values. The area under the curve (AUC) and confidence interval corresponds to the primary outcome.
doi:10.1371/journal.pone.0115852.g003
External Validation of Asthma Prediction Tool
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validation. The different age distributions at risk assessment including 1–2 years
old children in the original cohort may explain the lower performance measures.
Of note, prevalence and severity of asthma–like symptoms are higher in the
United Kingdom compared to Germany [28].
Wheezing in the past 12 months along with the use of asthma inhalers at 8 years
was the outcome used for model development. Our 8-years’ questionnaire asked
non-specifically for any drugs against respiratory disease including those
administered orally, leading to wider inclusion. A noteworthy feature of our
analysis was the assessment of various (secondary) outcome definitions. Those
criteria based solely on information from the 8-years’ questionnaire gave similar
performance and discrimination with the highest AUC of 0.89 for predicting
asthma supported by a physician’s diagnosis at 8 years. The asthma prediction
tool performed worse predicting any asthma up to age 20 years (AUC 0.75),
allergic asthma up to 20 years (AUC 0.80) and did not predict airway
responsiveness at 20 years (AUC 0.64).
Fig. 4. Calibration assessment, predicted probabilities vs. real asthma frequencies in eight equally
assigned groups. Exact 95%-confidence intervals for actual asthma frequency based on beta/binominal
distribution. Penalized B-Spline (2nd degree) aiding graphical interpolation (dotted line). Perfect calibration at
diagonal (dashed line). Primary inclusion, scoring, and outcome definitions.
doi:10.1371/journal.pone.0115852.g004
External Validation of Asthma Prediction Tool
PLOS ONE | DOI:10.1371/journal.pone.0115852 December 23, 2014 13 / 17
Appraisal
As expected for retrospective external validation, there was no perfect resemblance
of tools and criteria. But robustness of performance and discrimination against
changes of inclusion, scoring and outcome criteria gave confidence for the
applicability of the asthma prediction tool in settings outside the development
cohort.
Prediction usually performs best in the setting where the model is developed in,
either internally on the same or a subset of the original sample, or externally in the
same setting shifted geographically and/or in time [16, 18]. To our surprise, the
external validation that we performed in a different setting, the MAS-90 birth
cohort from Germany, gave even better performance, discrimination and
prediction. This could be due to differences in questionnaire administration: filled
by parents in the original cohort vs. based on face-to-face interviews in MAS-90,
the latter presumably with higher discriminatory power. Additionally, the LASSO
method (Least Absolute Shrinkage and Selection Operator) used for predictor
selection while developing the score aims at fewer factors in the final model and
higher external validity [29].
Table 5. Discrimination and Performance of the asthma prediction score in the MAS-90 birth cohort used for external validation.
n Cases$ (%)
Area under curve [95%-
CI]
Nagelkerke’s
R2*
Brier
score* Odds Ratio [95%-CI]
Primary inclusion, scoring, and outcome1 140 28 (20) 0.83 [0.75;0.91] 0.32 0.22 1.7 [1.4;2.1]
Secondary inclusion definitions
all available 841 48 (6) 0.80 [0.73;0.87] 0.26 0.18 1.8 [1.6;2.1]
non-allergic parents 412 9 (2) 0.84 [0.70;0.97] 0.26 0.12 2.0 [1.5;2.7]
wheezing 81 26 (32) 0.72 [0.61;0.84] 0.18 0.13 1.5 [1.2;2.0]
cough 80 13 (16) 0.91 [0.81;1.00] 0.55 0.45 2.1 [1.5;3.1]
Secondary scoring definitions
complement from earlier follow-ups 140 28 (20) 0.83 [0.75;0.90] 0.33 0.21 1.8 [1.4;2.2]
missing answers filled at random# 140 28 (20) 0.83 [0.75;0.91] 0.33 0.23 1.7 [1.4;2.2]
actual scores randomly shuffled# 140 28 (20) 0.55 [0.41;0.69] 0.01 0.01 1.0 [0.8;1.3]
Secondary outcome definitions
Wheeze at 8y 140 33 (24) 0.81 [0.73;0.89] 0.30 0.21 1.6 [1.3;2.0]
asthma drugs at 8y 140 33 (24) 0.82 [0.74;0.90] 0.32 0.23 1.7 [1.4;2.0]
physician’s diagnosis asthma (ever) 140 27 (19) 0.89 [0.84;0.95] 0.47 0.34 2.1 [1.6;2.7]
Secondary outcome definitions (later)
any asthma up to 20y 121 51 (42) 0.75 [0.66;0.84] 0.24 0.20 1.5 [1.3;1.8]
allergic asthma up to 20y 121 43 (36) 0.80 [0.72;0.88] 0.31 0.24 1.6 [1.3;2.0]
wheeze/asthma medication at 13y 113 14 (12) 0.86 [0.78;0.95] 0.36 0.23 2.0 [1.4;2.9]
wheeze/asthma medication at 20y 121 18 (15) 0.80 [0.68;0.91] 0.27 0.19 1.6 [1.3;2.1]
increased airway responsiveness at 20y 93 29 (31) 0.64 [0.52;0.77] 0.07 0.05 0.8 [0.7;1.0]
* rescaled to its maximum value; # 100 imputations, accounted for calculating confidence intervals; $ according to the corresponding outcome definition; 1
primary inclusion: cough or wheeze at 3 years – primary scoring: available items at 3 years – primary outcome: wheeze and asthma medication at 8 years;
Odds Ratio per 1-point increase in asthma prediction score; Secondary outcome definition details up to age 20 years in methods section; CI, confidence
interval.
doi:10.1371/journal.pone.0115852.t005
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A single prediction tool
Several independent attempts to predict asthma development from preschool
symptoms and presumed risk factors have been made, but none reached
widespread application in clinical practice [9]. Most tools were never validated
externally, never updated and refined further, and their health benefit never
assessed. Instead of incrementally improving existing prediction tools, new but
similar models with comparable sets of predictors were suggested.
Validating this tool externally, we see our analysis as a first step towards a single
and robust tool for the prediction of asthma development. This should be done in
other cohorts retrospectively, and ongoing or future longitudinal research on
asthma should consider collecting information detailed enough to facilitate
external validation of existing prediction tools. Comparing performance between
the model development cohort and various external settings provides valuable
insight into the influence of sampling and inclusion, selectiveness of scoring
information and outcome criteria.
From this general understanding, the existing model should be updated. This
includes the identification of additional factors not yet incorporated, and the
refining of weights from re-running the model. As the search for risk-factors has a
focus on true modifiable causes of the disease, this is not the case for estimating
the individual probability to develop asthma. Non-modifiable traits such as
parents’ allergy status, indicators of pre-clinical disease (eg, early wheezing),
sensitization, and environmental as well as behavioural exposures provide
valuable information for prediction modelling and should be used to improve the
model further.
Re-weighting prediction factors in external settings is often hampered by the
lack of detailed descriptions of the model building process, which should always
be made available online along initial publications, just as done in Pescatore et al.
[13]. In-depth sensitivity analyses are inevitable for robust re-weighting of
parameter estimates, accounting for inclusion, score coding and different
outcomes.
As a final step, impact analyses are essential to predict health benefits of
applying asthma prediction tools in clinical practice. They could prove useful for
early interventions, targeting prevention strategies, or improve sampling strategies
for research.
Conclusion
This first external validation of the newly developed asthma prediction tool
supports applicability outside the development cohort from Leicester, UK.
Performance and discrimination were better in our external sample compared to
internal validation, and robust against changes of inclusion, scoring and outcome
definitions. Being a tool for timely diagnosis based primarily on early symptoms,
we support its development by incorporating risk factors, externally refining the
underlying model and assessing the impact on health outcomes.
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